Popular on eTradeWire
- EZsolutions and Savify Partner to Deliver AI-Powered Online and Digital Solutions to Over 500,000 U.S. Businesses - 340
- K9 Technology President Files a Lawsuit Against Google LLC - 251
- BK Adventure Celebrates 10 Years of Glow: Join the Year-Long Celebration! - 212
- NCYS Names Distinguished Sports Leaders to Officer Positions for 2025 - 197
- Premium workspaces with exceptional hospitality to fuel your growth. Where professionals thrive - 185
- Uriel Medrano Joins RE1 Advisor as Property Manager/Realtor - 180
- The Perfect Book for Your Child's First Lost Tooth! - 178
- CROW receives funding to rebuild Sea Turtle Complex post Hurricane Ian - 160
- Pet Professional Guild Announces Corporate Partnership with the Phenix Advocacy Center - 154
- Vocs AI Announces Three Groundbreaking Features to Revolutionize AI Voice Generation - 144
Similar on eTradeWire
- ROC Announces Sponsorship of Lake Oswego High School Ski Team
- Dementia Beyond Drugs & Disease Symposium – March 6, 2025
- 14th annual Race of the Runways for Rotary 5k Run/Walk set for Saturday, February 22nd, 2025
- 2nd Annual Caring for the Cape event raises $162,450 for expanded health and wellness programs
- Catholic Community Foundation Grant Propels Ongoing (and Future) Success at Chosen Inc. of Wisconsin
- The Bridge Chiropractic Shares Practical Ways to Avoid Knee Pain
- Brighten Your Smile for Valentine's Day: Teeth Whitening Tips from a Dentist in Oceanside
- Say Goodbye to Bad Breath: Valentine's Day Oral Care Tips from a Dentist in Hot Springs
- Cielomar Recovery Launches Innovative Online Eating Disorder Treatment Program
- HUNY™ Launches Buzzworthy Wellness: Bee Energized with Shilajit Honey Sticks
The ROS1ders Issue RFA for $75K ROS1+ Cancer Innovation Award
eTradeWire News/10765143
Patient-founded nonprofit seeks to stimulate innovative research to improve outcomes for patients with ROS1+ cancers.
SACRAMENTO, Calif. - eTradeWire -- The ROS1ders is pleased to issue their 2024 Request for Application (RFA) to study ROS1-positive (ROS1+) cancer. The RFA is open to investigators who hold a doctorate degree and a faculty appointment at an academic or non-profit research institution anywhere in the world.
"While oral targeted therapies are approved to treat ROS1+ cancer, the drugs don't work for everyone, and they eventually stop working. We are committed to investing in research to improve patient outcomes," says Janet Freeman-Daily, MS, Engr, co-founder and president of The ROS1ders.
The ROS1+ Cancer Innovation Award aims to fund high-risk, high-reward projects focused on ROS1+ cancers. The one-year $75,000 seed grant can be used for pre-clinical, translational, or clinical research.
"Seed grants allow for the generation of initial data to support larger research endeavors," said D. Ross Camidge, MD, PhD, Professor of Medicine/Oncology at the University of Colorado and a member of The ROS1ders Scientific Advisory Board. "While some seeds fail, others grow into mighty trees - they can be the seeds of real breakthroughs."
More on eTradeWire News
The award program uses a two-step application process. The deadline for a letter of intent is May 3, 2024. Those invited to submit a full application must provide it by August 4, 2024. For more information, visit https://theros1ders.org/seed-grant-program.
About the ROS1ders
Founded by patients in 2015 and incorporated in 2019, The ROS1ders is the largest global group of patients and family members living with ROS1+ cancer. It seeks to improve outcomes for all ROS1+ cancers through community, education, and research. Membership in their private Facebook group exceeds 1200 people from over 30 countries. The nonprofit is internationally recognized in the oncology and patient advocacy communities as experts in their disease. Its resources include a medically-vetted website and collaboration with international ROS1+ clinicians, researchers and industry. Please visit theros1ders.org to learn more.
More on eTradeWire News
About ROS1+ Cancer
"While oral targeted therapies are approved to treat ROS1+ cancer, the drugs don't work for everyone, and they eventually stop working. We are committed to investing in research to improve patient outcomes," says Janet Freeman-Daily, MS, Engr, co-founder and president of The ROS1ders.
The ROS1+ Cancer Innovation Award aims to fund high-risk, high-reward projects focused on ROS1+ cancers. The one-year $75,000 seed grant can be used for pre-clinical, translational, or clinical research.
"Seed grants allow for the generation of initial data to support larger research endeavors," said D. Ross Camidge, MD, PhD, Professor of Medicine/Oncology at the University of Colorado and a member of The ROS1ders Scientific Advisory Board. "While some seeds fail, others grow into mighty trees - they can be the seeds of real breakthroughs."
More on eTradeWire News
- First Bancorp of Indiana, Inc. Announces Financial Results - December 31, 2024
- Bad Boy Is in Turmoil! What was Behind the Scenes of the Life of Biggie Smalls and Music Industry
- Celebrate National Margarita Day Feb. 22 with local Margaritaville properties
- Studio+ names Rachel Hunter principal of the Tampa office
- ROC Announces Sponsorship of Lake Oswego High School Ski Team
The award program uses a two-step application process. The deadline for a letter of intent is May 3, 2024. Those invited to submit a full application must provide it by August 4, 2024. For more information, visit https://theros1ders.org/seed-grant-program.
About the ROS1ders
Founded by patients in 2015 and incorporated in 2019, The ROS1ders is the largest global group of patients and family members living with ROS1+ cancer. It seeks to improve outcomes for all ROS1+ cancers through community, education, and research. Membership in their private Facebook group exceeds 1200 people from over 30 countries. The nonprofit is internationally recognized in the oncology and patient advocacy communities as experts in their disease. Its resources include a medically-vetted website and collaboration with international ROS1+ clinicians, researchers and industry. Please visit theros1ders.org to learn more.
More on eTradeWire News
- Js Art Gallery: A New International Art Space Promoting Unity Through Art
- FUSE: Premier Office Spaces with Hospitality-Driven Excellence
- Global Mobile Software, LLC Announces Sponsorship of Max Metcalfe, Goalkeeper at Stockport County FC
- Allison Dent Sets Sights on More Music in 2025
- Invenio IT Now Offers Dark Web ID Monitoring to Enhance Data Protection Services
About ROS1+ Cancer
- ROS1+ cancer is relatively rare, occurring in just 1-2% of non-small cell lung cancer (NSCLC). The incidence is thought to be similar in other types of cancer.
- Biomarker testing for ROS1 fusions is recommended in guidelines for non-small cell lung cancer (NSCLC), but for few other cancers.
- Patients are typically younger than the average NSCLC patient, have adenocarcinoma, and have no smoking history (a smoking history should not exclude patients from biomarker testing or targeted therapies).
- Oral targeted therapies are the recommended first-line treatment for metastatic ROS1+NSCLC and have increased the survival of patients by years. However, these drugs eventually stop working due to acquired resistance. The mechanisms of resistance are not well understood.
Source: The ROS1ders, Inc.
0 Comments
Latest on eTradeWire News
- Harlem Fine Arts Show Returns for 17th Year, Celebrating the African Diaspora
- January 2025 Jobs Report Highlights Persistent Racial Disparities Amid Modest Labor Market Gains
- Catholic Community Foundation Grant Propels Ongoing (and Future) Success at Chosen Inc. of Wisconsin
- Aries Industries Announces New Maryland/Delaware Dealer
- Introducing the American Federation Dollar (AFD): Gold-Backed Digital Currency Transforming Global
- The Bridge Chiropractic Shares Practical Ways to Avoid Knee Pain
- Wilderness Construction Shares Tips for Aging in Place with a Bathroom Renovation
- Roofman USA Expands Services Areas to Help More Michigan Homeowners
- Roofman USA Urges Homeowners to Consider Risks of DIY Roof Repairs
- A Legacy in Every Stitch: The Story Behind Moriah Dovelle's Kickstarter Campaign
- Top Sporting Minds to Meet in Manchester for New Data-Driven Conference
- Titan Pressure Washing Donates Their Services To Clean Treasure Coast Classical Academy
- HoverGrease 2 is Coming to Steam Next Fest: Play the Exclusive Demo Starting February 7
- Earn passive income through DAY Miner cloud mining in 2025
- Brighten Your Smile for Valentine's Day: Teeth Whitening Tips from a Dentist in Oceanside
- Say Goodbye to Bad Breath: Valentine's Day Oral Care Tips from a Dentist in Hot Springs
- MCS Innovator's Arena 2025 : Winners of India's Most Anticipated Tech Event Announced
- sliQue Robotics Launches Campaign to Transform Business Ecosystems
- New Sports Talk Podcast Bets N Banter Brings Expert Analysis, Sports Betting Breakdowns
- Mooka da Babe Has Inspired Expression of Love by New Single Valentine's Day Better Caring